



Featured Presenter



Jerry Kang
UCLA Professor of Law and Asian American Studies

Jerry Kang is Professor of Law, Professor of Asian American Studies, the inaugural Korea Times-Hankook Ilbo Endowed Chair in Korean American Studies and Law, and UCLA's inaugural Vice Chancellor (designate) for Equity, Diversity and Inclusion. A leading scholar on implicit bias and the law, Prof. Kang has published more than a dozen articles on the subject in leading journals including the Harvard Law Review. He regularly collaborates with leading experimental social psychologists on wide-ranging scholarly, educational, and advocacy projects.

Recognized by both the UCLA law school (Rutter Award) and the entire University as the best teacher of the year (Eby Art of Teaching Award), Prof. Kang is widely sought after as a speaker. Prof. Kang graduated magna cum laude from both Harvard College (physics) and Harvard Law School, where he was a supervising editor of the Harvard Law Review. After clerking for the Ninth Circuit Court of Appeals, he started his teaching career at UCLA in 1995 and has visited at both Georgetown and Harvard Law School. He was recently in residence as a Fellow at NYU Law's Straus Institute for the Advanced Study of Law & Justice.



Moderators and Panelists



Alexis Borisy
Chairman of the Board of Directors of Foundation Medicine, Inc.

Alexis Borisy is a successful biotechnology entrepreneur with more than 20 years of experience building and operating innovative science-based organizations. Mr. Borisy joined the life sciences venture capital firm Third Rock Ventures in 2009 to focus on the formation, development and strategy of new companies.

Prior to joining Third Rock Ventures, Mr. Borisy founded CombinatoRx in 2000, serving as its Chief Executive Officer and bringing the company public on the NASDAQ. He has raised more than \$1b in financing and business development deals, and has authored numerous scientific papers and patents. Trained in chemistry and chemical biology at Harvard where he was a Howard Hughes Predoctoral Fellow, Mr. Borisy was honored as the Massachusetts Institute of Technology's Technology Review Innovator of the Year. He was also chosen as the New England Entrepreneur of the Year in Life Sciences and was honored as a Presidential Scholar.

Mr. Borisy's undergraduate degree in chemistry is from the University of Chicago, and he did his graduate work in the laboratory of Dr. Stuart Schreiber at Harvard University. Mr. Borisy is a Trustee of the Boston Museum of Science, is a co-founder and former Chairman of FORMA Therapeutics, and serves on the board of the National Venture Capital Association.

Mr. Borisy's current roles include: Board Member of Editas Medicine; Board Member of REVOLUTION Medicine; Chairman of the Board of Warp Drive Bio; Board Member, Co-Founder, and former interim CEO of Blueprint Medicines and Chairman of the Board, Co-Founder and former interim CEO of Foundation Medicine.



9th Annual
DIRECTORS FORUM



Stuart M. Cable
Goodwin Procter partner and chair of M&A/Corporate Finance for its Technology Companies and Life Sciences Practices

Stuart Cable represents as outside general counsel public and private companies involved in the life sciences and technology sector. Mr. Cable also represents private equity and venture sources investing in such companies and investment banks serving such industries. He currently serves as Goodwin Procter's chair of M&A/Corporate Finance for its Tech and Life Sciences business practices and chair of the firm's practice group Incubator, and he leads the firm's initiative in expanding into Asia. He previously served as chair of the firm's Corporate Department, as chair of its Hiring Committee and as a member of its Executive and Allocations Committees.

Mr. Cable represents as outside general counsel a number of public companies, where he counsels boards of directors and management teams on corporate governance, mergers and acquisitions, disclosure and securities law matters. His recent M&A transactions include the sale of Onyx Pharmaceuticals to Amgen (\$10.4 billion), the sale of Eloqua to Oracle (\$1 billion), the majority sale of Foundation Medicine to Roche (\$1 billion), the sale of Idenix to Merck (\$3.8 billion), the sale of Pharmacyclics to AbbVie (\$21 billion) and the acquisition of Auspex by Teva (\$3.5 billion). Mr. Cable also serves regularly as counsel to issuers in IPOs, follow-on offerings and convertible debt transactions, and acts regularly as counsel for the underwriters in such transactions.

Mr. Cable earned his J.D. from Columbia Law School, his M.B.A. from the Tuck School of Business at Dartmouth and his A.B. from Dartmouth College.



9th Annual
DIRECTORS FORUM



Lawrence K. Fish

Former Chairman and Chief Executive Officer of Citizens Financial Group, Inc. and current Chairman of Houghton Mifflin Harcourt Publishing Company

Lawrence K. Fish is the former Chairman and CEO of Citizens Financial Group, Inc., a multi-state commercial bank holding company headquartered in Providence, Rhode Island. During his 17-year tenure, CFG grew 30-fold and became one of the 10 largest commercial bank holding companies in the United States in total assets and deposits. It operates its branch network in 13 states through its Citizens Bank and Charter One brands, and has non-branch retail and commercial offices in about 40 states.

Currently Fish is Chairman of Houghton Mifflin Harcourt, the largest educational publishing company in the United States with principal offices in Orlando, Boston, Austin and Chicago. The company employs several thousand people and is the largest publisher of K-12 textbooks in America as well as publishing adult fiction, non-fiction and a wide selection of children's book titles. He also is a Director of Textron Inc., a leading global multi-industry company with brands including Cessna, Beechcraft, Bell Helicopter and E-Z-Go golf carts, and Tiffany & Co., a leading American luxury brand with stores throughout the United States and worldwide.

Fish is a graduate of Drake University and the Harvard Graduate School of Business Administration. He is also the recipient of honorary doctorate degrees from Drake University, Providence College, Bryant College, Roger Williams University, Johnson & Wales University and the University of Massachusetts. He is a member of the American Academy of Arts and Sciences.



Lisa R. Haddad

Goodwin Procter partner and member of the firm's M&A/Corporate Governance Practice

Lisa Haddad, a partner in the firm's Business Law Department, focuses on mergers and acquisitions, corporate governance, securities offerings, securities law compliance for public companies, and general corporate matters. Ms. Haddad is a member of Goodwin Procter's M&A/Corporate Governance Practice.

Ms. Haddad has extensive experience in representing buyers and sellers in merger and acquisition transactions involving both public and private companies. In this area, she has a special focus on public company mergers and acquisitions.

Ms. Haddad also advises public companies on a wide variety of corporate and securities matters, including offerings of equity and debt securities. Her corporate finance experience includes IPOs, public "shelf" offerings and private placements of securities. Ms. Haddad also represents public companies as general corporate and securities law counsel, providing advice in all aspects of corporate governance and securities law compliance.

Ms. Haddad earned her J.D. from Harvard Law School and her B.B.A. from the University of Massachusetts.



9th Annual
DIRECTORS FORUM



Paul H. Luehr
Managing Director and Chief Privacy Officer of Stroz Friedberg

Paul Luehr is Managing Director and Chief Privacy Officer of Stroz Friedberg, a global risk management firm that specializes in digital forensics, data privacy and security, electronic discovery, business intelligence, and investigations. Mr. Luehr supervises rapid responses to national data breaches, global FCPA and antitrust investigations, privacy assessments, and trade secret cases. He also oversees the company's healthcare privacy and security practice. He is a former federal cybercrimes prosecutor and FTC Assistant Director who worked on matters ranging from Internet fraud and consumer privacy to the post-9/11 search of terrorist Zacarias Moussaoui's laptop. He has appeared on national television, in The Wall Street Journal, The New York Times, and was featured by Business Week as one of the nation's top cyber-cops. Mr. Luehr is an author and frequent speaker and he has lectured before the FBI Academy and traveled abroad as a U.S. State Department Speaker on commerce and cybercrime. He is a graduate of Harvard University and the UCLA School of Law.



Michael Pellini, M.D.
Chief Executive Officer and Director of Foundation Medicine, Inc.

Dr. Pellini joined Foundation Medicine as President and Chief Executive Officer in May 2011, bringing a breadth of experience in life sciences and the clinical diagnostics and laboratory industries to the company. Dr. Pellini came to Foundation Medicine from Clariant, a GE Healthcare Company, where he held the position of President and Chief Operating Officer. Dr. Pellini joined GE Healthcare through the integration of Clariant, Inc., where he worked with the company's leadership team to drive operational excellence and reimbursement strategies in parallel with the development and commercialization of multiple diagnostic tests. Dr. Pellini's leadership was instrumental in building Clariant to the highly successful acquisition by GE Healthcare in October 2010.

Prior to his tenure with Clariant, Dr. Pellini served as Vice President, Life Sciences at Safeguard Scientifics, Inc. where he leveraged his business and medical expertise to explore new market opportunities and to support Safeguard's partner companies. Prior to Safeguard, he was Executive Vice President and Chief Operating Officer at Lakewood Pathology Associates, a national molecular pathology services company, which was acquired by Water Street Healthcare Partners in 2006. Previously, Dr. Pellini was an Entrepreneur-in-Residence at BioAdvance, where he was responsible for identifying early-stage life science opportunities. He also served as President and Chief Executive Officer of Genomics Collaborative, Inc., a Boston-based biotech firm that was acquired by SeraCare Life Sciences, Inc. in 2004.

Dr. Pellini received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College of Thomas Jefferson University. He is a board member of the Personalized Medicine Coalition and serves on the President's Leadership Council of Jefferson Medical College.



Gino Santini
Chairman of the Board, AMAG Pharmaceuticals, Inc.

Gino Santini is the Chairman of the Board of AMAG Pharmaceuticals (NASDAQ: AMAG), and a member of the boards of Horizon Pharma plc (NASDAQ: HZNP), SORIN SpA (SRN.MI), Vitae Pharmaceuticals (NASDAQ: VTAE), Collegium Pharmaceutical (NASDAQ: COLL), Intarcia Therapeutics, Allena Pharmaceuticals, and Artax Biopharma. He is an advisor of European and US venture capital, pharmaceutical and biotechnology companies since 2011, when he retired after a

27-year career at Eli Lilly & Co.

His last role at Eli Lilly was Senior Vice President of corporate strategy and business development and he had been a member of the Executive Committee since 2004, reporting to the CEO. He was President, U.S. operations from 1999 to 2004, responsible for all operational and commercial activities in the United States and sales of over USD 7 Bil/year.

Mr. Santini was born in Cesena (Italy) and holds a degree in Mechanical Engineering from the University of Bologna (1981) and a Master of Business Administration from the Simon School of Business, University of Rochester (1983). He started his career with Eli Lilly as Financial Planning Associate in 1983 and he had various roles in finance and marketing in Italy and in the United States. In 1990 he was appointed Pharmaceutical Director for the Belgian business unit and in 1991 General Manager of Eli Lilly Compania de Mexico in Mexico City. He was Area Director for Latin America in 1994-95, Vice President of Corporate Strategy and Business Development in 1996, and President della Women's Health Business Unit in 1997.

Mr. Santini is a past Chairman of the Board of the National Pharmaceutical Council and of Noble of Indiana, a nonprofit agency serving individuals with developmental disabilities. He also served on the Board of Directors for United Way and the Executive Committee and Board of the Indianapolis Chamber of Commerce. He is an Italian citizen and lives in the United States with his family.



9th Annual
DIRECTORS FORUM



Robert Schechter
Chairman of the Board, PTC, Inc.

Bob has over 30 years of broad-based executive and board level leadership experience in a range of technology and telecommunications businesses. Currently a corporate board member, investor and advisor to several early stage businesses, he serves on the Board of PTC, Inc., Exa Corporation and Tremor Video.

Bob was previously CEO and Chairman of NMS Communications, a software/hardware developer of telecommunications technologies, where he led the company through the industry transition to IP networks. Prior to NMS, Bob was an executive at Lotus Development Corp., first as Chief Financial Officer and later as Head of the International Business Group. Earlier in his career, he was a partner at Coopers & Lybrand, where he led the firm's Technology Practice in the Northeast. Previous board service includes Unica Corporation (UNCA), Soapstone Networks (SOAP), Moldflow (MFLO) and Mapinfo, Inc. (MAPS).

He is a past chair of the Massachusetts Network and Communications Council and the Boston Children's Museum, former board member of Squashbusters, Inc., and currently serves on the Board of Temple Beth Elohim.

Bob is a graduate of Rensselaer Polytechnic Institute and the Wharton School of the University of Pennsylvania.



9th Annual
DIRECTORS FORUM



David Schenkein, M.D.
Chairman of the Transaction Committee of Foundation Medicine, Inc.

Dr. Schenkein joined Agios in August 2009 as the Chief Executive Officer and a member of their Board of Directors and has been a hematologist and medical oncologist for more than 20 years. He currently serves as an adjunct attending physician in hematology at Tufts Medical Center and is a member of the board of directors for the Biotechnology Industry Organization, the world's largest biotechnology trade association, a position he has held since 2012. Prior to joining Agios, from March 2006 to July 2009, Dr. Schenkein was the Senior Vice President, clinical hematology/oncology at Genentech, Inc., a pharmaceutical company, where he was responsible for numerous successful oncology drug approvals and leading the medical and scientific strategies for their BioOncology portfolio. While at Genentech, he served as an adjunct clinical Professor of Medical Oncology at Stanford University School of Medicine.

Prior to joining Genentech, he served as the Senior Vice President of clinical research at Millennium Pharmaceuticals, Inc. (a wholly-owned subsidiary of Takeda Pharmaceuticals Company Limited), overseeing the clinical development and worldwide approval of Velcade®, a first-in-class cancer therapy now approved to treat multiple myeloma and non-Hodgkins lymphoma. He currently serves on the Board of Directors of Foundation Medicine, Inc., bluebird bio, Inc., and Blueprint Medicines, Inc.

Dr. Schenkein holds a B.A. in chemistry from Wesleyan University and an M.D. from the State University of New York Upstate Medical School.



Gerard M. Stegmaier
Goodwin Procter partner and member of the firm's Privacy & Data Security and Technology Companies Practices

Gerry Stegmaier is a partner and a member of the firm's Privacy & Data Security and Technology Companies Practices. He focuses his practice on public and private corporate governance, intellectual property and Internet issues, especially as they relate to privacy, information security and consumer protection. An experienced and pragmatic litigator, Mr. Stegmaier focuses a significant part of his practice on pre-litigation and advisory services relating to business strategy for privacy by design, data protection, intellectual property, and emerging technologies and markets, often acting as outside product counsel to leading innovators and disruptive technology companies.

Mr. Stegmaier, designated as a Certified Information Privacy Professional by The International Association of Privacy Professionals, brings a practical approach grounded in real world experience to serving clients and solving problems. His experience spans litigation, transactional and regulatory matters. In recent years, he has helped many automotive, health information technology, data broker and advertising technology companies recognize and govern data as an asset.

Mr. Stegmaier earned his J.D. and B.A. from George Mason University School of Law and his M.A. from Catholic University of America.